Procter & Gamble's Heft Proves Unwavering in Q2

We intend to hold the line on our long-term expectations for 4% annual sales growth and operating margins in the mid-20s for the wide-moat company.

Securities In This Article
Procter & Gamble Co
(PG)

Leading up to wide-moat Procter & Gamble’s PG second-quarter earnings release the overarching question remained anchored in whether it would be able to continue the string of mid- to high-single-digit organic sales marks that have come to characterize the results over the past two and a half years. And in that regard, the firm did not disappoint, posting an 8% underlying sales gain (driven by 5% higher volumes and a 3% benefit from increased prices and favorable mix), a far cry from the low-single-digit levels the business was chalking up just a few short years ago. But we don’t surmise P&G’s top-line momentum is the product of a shift in focus away from driving profitability improvement. P&G also boasted gross and operating margin expansion, up 150 and 250 basis points, respectively, to 53.1% and 27.2%, reflecting the benefit of sales leverage and productivity gains that offset a 7% increase in advertising for its leading brands.

When taken together, management again bumped up its fiscal 2021 outlook, now calling for 5%-6% organic sales growth (from 3%-4% most recently) and core EPS growth of 8%-10% (from 5%-8%), which outpace our 4% and 7% respective pre-print marks. While we intend to amend our near-term forecast in light of its year-to-date performance (which will likely boost our $113 fair value estimate by $1-$2 per share), we don’t expect competitive angst will lay dormant over an extended horizon (as it has since the pandemic took hold). As such, we intend to hold the line on our long-term expectations for 4% annual sales growth and operating margins in the mid-20s (up from the low-20s average the past three years).

And despite this stellar performance, it’s clear expectations have been raised, as shares slumped at a low-single-digit clip on the news. However, given the stock still sits at a mid-teens premium to our assessment of intrinsic value, we’d suggest investors remain on the sidelines until a more favorable risk/reward opportunity arises.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

More in Stocks

About the Author

Erin Lash, CFA

Sector Director
More from Author

Erin Lash, CFA, is a sector director, AM Consumer, for Morningstar*. In addition to leading the sector team, she covers packaged food and household and personal care companies. Beyond managing a team of nine analysts and associates covering an array of consumer firms, Lash also conducts fundamental analysis of 13 multi-billion-dollar market capitalization firms in the packaged food and household and personal care space.

Before joining Morningstar in 2006, Lash spent four years as an investment analyst covering retail, transportation, and technology firms for State Farm Insurance. In this capacity, Lash analyzed financial statements, business strategy, and fundamentals of owned companies and potential investments, presenting her recommendations based on this analysis to State Farm portfolio managers for ownership consideration.

Lash holds a bachelor’s degree in finance from Bradley University’s Foster College of Business. She also holds a master’s degree in business administration, with concentrations in accounting and finance, from the University of Chicago Booth School of Business. Lash has completed the Chartered Financial Analyst® designation. She ranked second in the food and tobacco industry in The Wall Street Journal’s annual “Best on the Street” analysts survey in 2013, the last year the survey was conducted.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center